| abstract |
Disclosed herein are compositions and methods involving or derived from anti-JAG1 antibodies. More specifically, disclosed herein are fully human antibodies that bind JAG1, JAG1-binding fragments and derivatives of such antibodies, and JAG1-binding polypeptides comprising such fragments. In addition, disclosed herein are nucleic acids encoding such antibodies, antibody fragments and derivatives, and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives, and polypeptides, and the use of such Methods of antibodies, antibody fragments and derivatives, and polypeptides, including methods of treating or diagnosing a subject with a JAG1-associated disorder or condition. Also disclosed herein is use in the treatment of JAG1 expressing tumors (including hepatocellular carcinoma and squamous cell carcinoma), and selected from rheumatoid arthritis, experimental lung injury, atherosclerosis, chronic liver disease caused by hepatitis C virus, Non-oncological disease approaches to ischemic myocardial injury and heart failure. |